Pfizer’s Metsera hunger sees it beat Novo Nordisk’s obesity biopharma offer
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
List view / Grid view
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.
Novo Nordisk’s “bold” $6.5 billion bid subject to a final verdict by Metsera’s board of directors.
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.